PD
SNDX icon

Point72 (DIFC)’s Syndax Pharmaceuticals SNDX Stock Holding History

Point72 (DIFC)’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$258K Buy
16,791
+12,464
+288% +$163K 0.02% 401
2025
Q2 		$40.5K Buy
+4,327
New +$47.6K ﹤0.01% 1103
2025
Q1 		– Sell
-9,661
Closed -$128K – 2041
2024
Q4 		$128K Sell
9,661
-1,003
-9% -$17.2K ﹤0.01% 960
2024
Q3 		$205K Sell
10,664
-73
-0.7% -$1.51K 0.01% 842
2024
Q2 		$220K Buy
+10,737
New +$225K 0.01% 831

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Point72 (DIFC)'s SNDX Position: Q3 2025 in Review

Point72 (DIFC) increased its Syndax Pharmaceuticals (SNDX) stake by 288% in Q3 2025, buying an estimated $163K and bringing the position to 16,791 shares worth $258K. The position accounts for 0.02% of the portfolio, ranked #401.

Point72 (DIFC) first reported a position in SNDX in Q2 2024 and has held it in 5 quarters since. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Point72 (DIFC) held 16,791 shares of Syndax Pharmaceuticals worth $258K as of Q3 2025.
  • Point72 (DIFC) bought 12,464 Syndax Pharmaceuticals shares in Q3 2025, an estimated $163K.
  • Syndax Pharmaceuticals made up 0.02% of Point72 (DIFC)'s portfolio in Q3 2025, its #401 holding.
  • Point72 (DIFC) first reported a position in Syndax Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.